Low-density lipoprotein receptor–negative compound heterozygous familial hypercholesterolemia: Two lifetime journeys of lipid-lowering therapy.

We present the case history of 2 patients with low-density lipoprotein receptor–negative compound heterozygous familial hypercholesterolemia who did not receive lipoprotein apheresis. We describe the subsequent effect of all lipid-lowering medications during their life course including resins, statins, ezetimibe, nicotinic acid/laropiprant, mipomersen, and lomitapide. These cases tell the story of siblings affected with this rare disease, who are free of symptoms but still are at a very high cardiovascular disease risk, and their treatment from childhood. [ABSTRACT FROM AUTHOR]